Helen M. Thackray, Chief R&D Officer at BIOCRYST PHARMACEUTICALS INC (BCRX), sold 7,600 shares at $16.20 ($123K) on 2022-04-01, disclosed to the SEC on 2022-04-04.
Open-market sale of $123k BCRX by Chief R&D Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| BCRX | SELL | 2022-12-19 | $34K | — | Filing → |
| GLYC | SELL | 2017-12-12 | $30K | — | Filing → |
| GLYC | SELL | 2017-09-18 | $26K | — | Filing → |